^
Association details:
| Biomarker: | TAp63 overexpression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Transcription Factor TAp63 Exerts Pro-Survival Effects in Chronic Lymphocytic Leukemia Acting through the BCL2 Pathway
Published date:
11/01/2018
Excerpt:
...we additionally assessed ex vivo the effect of the BCL2 inhibitor Venetoclax in primary CLL cells of both TAp63 high (n=8) and TAp63 low (n=6) cases. Cell viability was measured by flow cytometry at 24 and 48 hours after treatment. TAp63 high cases were more resistant to treatment with Venetoclax as they showed no statistically significant reduction in cell viability compared to the respective (DMSO-treated) controls, in contrast to TAp63 low cases (24h: FD=3.63, p=0.004; 48h: FD=7.17, p=0.005).
DOI:
10.1182/blood-2018-99-118167
